Author

Paul D. Carlson

Observed name: Paul Carlson

Institution: Cogent Biosciences (United States)

Observed institutions: Northwestern University, University of Minnesota, Cornell University, Cogent Biosciences (United States)

ORCID: 0000-0002-4819-6503

Observed ORCID: 0000-0002-4819-6503

OpenAlex ID: A5076679108

De novo-designed translation-repressing riboregulators for multi-input cellular logic

2019 · Jongmin Kim, Yu Zhou, et al. · Nature Chemical Biology · 155

PDF

Computational design of three-dimensional RNA structure and function

2019 · Joseph D. Yesselman, Daniel Eiler, et al. · Nature Nanotechnology · 78

A ligand-gated strand displacement mechanism for ZTP riboswitch transcription control

2019 · Eric J. Strobel, Luyi Cheng, et al. · Nature Chemical Biology · 71

PDF

Detection of viral RNAs at ambient temperature via reporter proteins produced through the target-splinted ligation of DNA probes

2023 · Elizabeth A. Phillips, Adam D. Silverman, et al. · Nature Biomedical Engineering · 44

PDF

Using in-cell SHAPE-Seq and simulations to probe structure–function design principles of RNA transcriptional regulators

2016 · Melissa K. Takahashi, Kyle E. Watters, et al. · RNA · 37

PDF

Characterizing the Structure–Function Relationship of a Naturally Occurring RNA Thermometer

2017 · Sarai Meyer, Paul D. Carlson, et al. · Biochemistry · 27

PDF

SnapShot: RNA Structure Probing Technologies

2018 · Paul D. Carlson, Molly E. Evans, et al. · Cell · 17

PDF

Automated image analysis programs for the quantification of microvascular network characteristics

2015 · Kristen T. Morin, Paul D. Carlson, et al. · Methods · 17

De novo Design of Translational RNA Repressors

2018 · Paul D. Carlson, Cameron J. Glasscock, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 16

PDF

Elements of RNA Design

2018 · Paul D. Carlson, Julius B. Lucks · Biochemistry · 5

Abstract 410: Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with selectivity for mutant KRAS over HRAS and NRAS.

2026 · John Fischer, Kim Alley, et al. · Cancer Research

Preclinical characterization of a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor

2025 · Mark Chicarelli, Michelle Crow, et al. · Blood

PDF

Abstract B024: Identification of a potent KRAS (ON) inhibitor clinical candidate series with selectivity for mutant KRAS over HRAS and NRAS

2025 · John Fischer, Kim Alley, et al. · Molecular Cancer Therapeutics

Abstract 6974: Identification of a potent KRAS (ON) inhibitor with selectivity for mutant KRAS over HRAS and NRAS

2025 · Keith Koch, Kim Alley, et al. · Cancer Research

INSPECTR assay protocol for sensitive SARS-CoV-2 enabled by rolling circle amplification

2023 · Elizabeth A. Phillips, Adam D. Silverman, et al. · Research Square

PDF

Works count: 15

Citation count: 467

H-index: 9

I10-index: 9